The results of Phase IIa with open-label and the subsequent phase of open-label trial III reinforce the findings from a previous short-term trial that adolescents with moderate to severe atopic dermatitis or eczema may experience significant improvement. The results of these latest studies, published in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the drugs during treatment up to 52 weeks.
Dupilumab works by stopping the action of certain substances in the body that cause eczema symptoms. Specifically, it is a monoclonal antibody against alpha receptor-indoleukin-4.
Adolescents with moderate to severe atopic dermatitis have a high burden of disease that adversely affects their quality of life, and patients require long-term therapies. The results of these studies show that dupilumab provides significant and sustained clinical benefit to these patients with an acceptable safety profile. "
Dr. Ashish Bansal, senior author of Regeron Pharmaceuticals, in Taritown, New York
Cork, MJ, et al. (2019) Dupilumab in Adolescents with Uncontrolled Moderate – to – Severe Atopic Dermatitis: Results from a Phase IIa Lab Test and a Follow – up Phase III Extension. British Journal of Dermatology. doi.org/10.1111/bjd.18476.